A novel real-time CTL assay to measure designer T-cell function against HIV Env+ cells

Journal of Medical Primatology

Volumn 43, Issue 5, 2014, Pages 341-348

  Maclean, Andrew G ^a   Walker, Edith ^a   Sahu, Gautam K ^b   Skowron, Gail ^b   Marx, Preston ^a   von Laer, Dorothee ^c   Junghans, Richard P ^b   Braun, Stephen E ^a  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b Roger William Medical Center   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

CD4 CAR; Cytotoxic T lymphocytes; DTc; MaC46; Rhesus macaque; Transduced T cells

Indexed keywords

CD3 ANTIBODY; CHIMERIC ANTIGEN RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MEMBRANE ASSOCIATED C46 PEPTIDE; MONOCLONAL ANTIBODY CD28; PEPTIDES AND PROTEINS; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ADOPTIVE TRANSFER; ANALYZER; ANIMAL CELL; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL KILLING; CELL SPECIFICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DESIGNER T CELL; EXTRACELLULAR MATRIX; FEASIBILITY STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSURVEILLANCE; IMPEDANCE; INTRACELLULAR SIGNALING; MICROPLATE READER; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TARGET CELL DESTRUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ENVELOPE; VIRUS REPLICATION; XCELLIGENCE RTCA DP DEVICE; ANIMAL; ELECTRIC CONDUCTIVITY; GENE VECTOR; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PHYSIOLOGY; RHESUS MONKEY;

MACACA MULATTA;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ELECTRIC CONDUCTIVITY; ELECTRIC IMPEDANCE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HEK293 CELLS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; MACACA MULATTA; T-LYMPHOCYTES, CYTOTOXIC; VIRUS REPLICATION;

EID: 84927702536     PISSN: 00472565     EISSN: 16000684     Source Type: Journal    
DOI: 10.1111/jmp.12137     Document Type: Article

References (30)

1. Beaudoin E, Bais A, Junghans R: Sorting vector producer cells for high transgene expression increases retroviral titer. J Virol Methods 2008; 148:253-9.
2. Braun SE, Aronovich EL, Anderson RA, Crotty PL, McIvor RS, Whitley CB: Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase. Proc Natl Acad Sci USA 1993; 90:11830-4.
3. Braun SE, Shi X, Qiu G, Wong FE, Joshi PJ, Prasad VR, Johnson RP: Instability of retroviral vectors with HIV-1-specific RT aptamers due to cryptic splice sites in the U6 promoter. AIDS Res Ther 2007; 4:24.
4. Braun SE, Taube R, Zhu Q, Wong FE, Murakami A, Kamau E, Dwyer M, Qiu G, Daigle J, Carville A, Johnson RP, Marasco WA: In vivo selection of CD4(+) T cells transduced with a gamma-retroviral vector expressing a single-chain intrabody targeting HIV-1 tat. Hum Gene Ther 2012; 23:917-31.
5. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM: A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002; 5:788-97.
6. + T cells. Nature 2002; 417:95-8.
7. Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan G, Kunert R, Baum C, Choi I, Alexandrov A, von Laer D: Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 2004; 78:568-75.
8. Emtage PC, Clarke D, Gonzalo-Daganzo R, Junghans RP: Generating potent Th1/Tc1 T cell adoptive immunotherapy doses using human IL-12: harnessing the immunomodulatory potential of IL-12 without the in vivo-associated toxicity. J Immunother 2003; 26:97-106.
9. Erskine CL, Henle AM, Knutson KL: Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system. J Vis Exp 2012; 66:e3683.
10. + T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS ONE 2010; 5:e12357.
11. Kulkarni V, Rosati M, Bear J, Pilkington GR, Jalah R, Bergamaschi C, Singh AK, Alicea C, Chowdhury B, Zhang GM, Kim EY, Wolinsky SM, Huang W, Guan Y, LaBranche C, Montefiori DC, Broderick KE, Sardesai NY, Valentin A, Felber BK, Pavlakis GN: Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques. Hum Vaccin Immunother 2013; 9:2081-94.
12. Kute T, Stehle JR Jr, Ornelles D, Walker N, Delbono O, Vaughn JP: Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells. Oncoimmunology 2012; 1:810-21.
13. Laugel B, van den Berg HA, Gostick E, Cole DK, Wooldridge L, Boulter J, Milicic A, Price DA, Sewell AK: Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J Biol Chem 2007; 282:23799-810.
14. Melikyan GB, Egelhofer M, von Laer D: Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J Virol 2006; 80:3249-58.
15. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA, Pennathur-Das R, Hege KM: Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96:785-93.
16. Pan C, Liu S, Jiang S: HIV-1 gp41 fusion intermediate: a target for HIV therapeutics. J Formos Med Assoc 2010; 109:94-105.
17. Peper JK, Schuster H, Loffler MW, Schmid-Horch B, Rammensee HG, Stevanovic S: An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. J Immunol Methods 2014; 405:192-8.
18. Quereda JJ, Martinez-Alarcon L, Mendoca L, Majado MJ, Herrero-Medrano JM, Pallares FJ, Rios A, Ramirez P, Munoz A, Ramis G: Validation of xCELLigence real-time cell analyzer to assess compatibility in xenotransplantation with pig-to-baboon model. Transplant Proc 2010; 42:3239-43.
19. Ramis G, Martinez-Alarcon L, Majado MJ, Quereda JJ, Mendonca L, Herrero-Medrano JM, Abellaneda JM, Rios A, Lopez-Navas A, Ramirez P, Munoz A: Assessment of in vitro heparin complement regulation capacity during real-time cell analyzer antibody-mediated cytolysis assay: compatibility studies for pig-to-baboon xenotransplantation. Transplant Proc 2012; 44:1584-8.
20. Renner NA, Sansing HA, Inglis FM, Mehra S, Kaushal D, Lackner AA, Maclean AG: Transient acidification and subsequent proinflammatory cytokine stimulation of astrocytes induce distinct activation phenotypes. J Cell Physiol 2013; 228:1284-94.
21. Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP: Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology 2013; 446:268-75.
22. Sansing HA, Renner NA, MacLean AG: An inverted blood-brain barrier model that permits interactions between glia and inflammatory stimuli. J Neurosci Methods 2012; 207:91-6.
23. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH: Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012; 4:132ra153.
24. Teng Z, Kuang X, Wang J, Zhang X: Real-time cell analysis-a new method for dynamic, quantitative measurement of infectious viruses and antiserum neutralizing activity. J Virol Methods 2013; 193:364-70.
25. Walker REBC, Natarajan V, Baseler M, Hege KM, Metcalf JA, Stevens R, Hazen A, Blaese RM, Chen CC, Leitman SF, Palensky J, Wittes J, Davey RT Jr, Falloon J, Polis MA, Kovacs JA, Broad DF, Levine BL, Roberts MR, Masur H, Lane HC: Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000; 96:467-74.
26. Wilen CB, Tilton JC, Doms RW: Molecular mechanisms of HIV entry. Adv Exp Med Biol 2012; 726:223-42.
27. Witkowski PT, Schuenadel L, Wiethaus J, Bourquain DR, Kurth A, Nitsche A: Cellular impedance measurement as a new tool for poxvirus titration, antibody neutralization testing and evaluation of antiviral substances. Biochem Biophys Res Commun 2010; 401:37-41.
28. Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K: Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 2011; 17:5060-70.
29. Yang W, Beaudoin EL, Lu L, Du Pasquier RA, Kuroda MJ, Willemsen RA, Koralnik IJ, Junghans RP: Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML). Int Immunol 2007; 19:1083-93.
30. + T cells and maintenance of virus specific immunity in a primate AIDS model. Blood 2013; 122:179-87.